URGNUroGen Pharma Ltd.

$918M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M

Gross Profit

$3M91.1% margin

Operating Income

-$29M-841.5% margin

Net Income

-$29M-832.6% margin

EPS (Diluted)

$-1.31

QoQ Revenue Growth

+830.4%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$26M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$140M

Total Liabilities

$19M

Stockholders' Equity

$121M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$0	—
Gross Profit	$3M	-$23M	+113.4%
Operating Income	-$29M	-$23M	-24.2%
Net Income	-$29M	-$22M	-29.5%

URGN Q3 2020 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena